‘Competition law in the pharmaceutical sector’ conference returns with IPKat readers’ discounted fee
Readers interested in competition law as applied to the pharmaceutical sector will be pleased to learn that,
this year, the traditional ‘Competition law in the pharmaceutical sector’ conference is returning as an in-person event taking place in Brussels on 2 December 2021.
this year, the traditional ‘Competition law in the pharmaceutical sector’ conference is returning as an in-person event taking place in Brussels on 2 December 2021.
This year’s programme features 19 multi-jurisdictional speakers, including representatives of the European Commission, senior counsel from several leading pharma companies and a host of specialised advisors.
According to the organizers, participation in the conference will allow attendees, including those concerned with compliance issues, to gain insights into what the competition authorities are doing, the implications of the latest patent cases, the new Article 22 referral guidelines, pricing, distribution and more.
The IPKat has also negotiated a special discount for its readers. By using FKW83392IPKE at checkout, it will be possible to claim a 15% discount in the registration fee.
For further information and to register, just click here.
‘Competition law in the pharmaceutical sector’ conference returns with IPKat readers’ discounted fee
Reviewed by Eleonora Rosati
on
Tuesday, October 26, 2021
Rating:
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html